

Covid-19 Monoclonal Antibody Emergency Use Authorization (EUA) Checklist

Criteria for Use:

This EUA is for the use of Covid-19 Monoclonal Antibody for the treatment of mild to moderate COVID19 in adults and pediatric patients with a positive result for SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kg, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.

- Covid-19 Monoclonal Antibody should be administered as soon as possible after a positive viral test for SARS-CoV2 and within 7 days of exposure, asymptomatic positive test and/or symptom onset.
-

Patient has **at least one** of the following High-Risk criteria (**check all that apply**):

- | | |
|--|--|
| <input type="checkbox"/> Body mass index (BMI) >25 | <input type="checkbox"/> Cardiovascular Disease/HTN |
| <input type="checkbox"/> Age \geq 65 years | <input type="checkbox"/> Chronic respiratory disease |
| <input type="checkbox"/> Chronic kidney disease | <input type="checkbox"/> Pregnancy |
| <input type="checkbox"/> Diabetes | <input type="checkbox"/> Neurodevelopmental disorder |
| <input type="checkbox"/> Immunosuppressive disease or currently <input type="checkbox"/> | <input type="checkbox"/> Sickle Cell Disease |
| <input type="checkbox"/> Receiving immunosuppressive treatment | |

- Are 12 – 17 years of age AND >40kg
 - o BMI \geq 85th percentile for their age and gender based on CDC growth charts, [CDC growth charts](#),
 - o One of the above criteria
 - o Medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR chronic respiratory disease that requires daily medication for control.
-

EXCLUSION Criteria *NOT* met.

Covid-19 Monoclonal Antibody is *not* authorized for patients:

- o hospitalized due to COVID-19, OR
- o require oxygen therapy due to COVID-19, OR
- o require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.
- o with known hypersensitivity to any ingredient.